



WHAT IS CLAIMED IS:

1. A compound of the formula:



wherein X is a linker group having 2-5 functional groups or is absent, n = 1, and Formula II is



wherein R, A, B, C, D, E, F, G, H, I, J, and K are selected from the following or may be absent, and wherein K is Arg or an Arg derivative:

R	A -1	B 0	C 1	D 2	E 3	F 4	G 5	H 6	I 7	J 8	K 9
Absent or 3,3DP Aaa Ac	Absent or DmK Lys Lys(eF lu)	Absent or Apc Arg DArg	Absent or ApC Arg DmK	Absent Or MeP Nig NMF	Absent or Hyp Pro	Absent or Ava BAIa Dpr	Absent or Add Aud CpG	Absent or Arg Gly Pac	Absent or 2Nal DCpG DF5F	Absent or 2Nal 2Nal- NH ₂	Absent or Arg Arg(H) Arg- CH ₂ O H Arg- NH ₂ Arg(N O ₂) Arg- OMe DArg DArg- NH ₂ DArg(NO ₂)
Aca	NiK	DLys	NiK	Pro		Eac	DDM F	Pac	DIgl	3,4F2 F	Arg- NH ₂ Arg(N O ₂) Arg- OMe DArg DArg- NH ₂ DArg(NO ₂)
BAPg	PzO	DmK	NiO			Gly	DMF	Ser	DPFF	3Pal	Arg- NH ₂ Arg(N O ₂) Arg- OMe DArg DArg- NH ₂ DArg(NO ₂)
Cca		DniK	PaF				Eac	Thr	DPhe	Ac6c	Arg- OMe DArg DArg- NH ₂ DArg(NO ₂)
Cin Dca		DpaF DPzK	PzO				Igl Lys		DTic Gly	Aic Ana	Arg- OMe DArg DArg- NH ₂ DArg(NO ₂)
Dcg		DPzO					Pac		mABz	Apb	Arg- OMe DArg DArg- NH ₂ DArg(NO ₂)
Dhq Dmac Dpa		Lys NiK PaF					Phe Thi		pABz Pac PaF(D cg)	Apb Atpc Bip	Arg- OMe DArg DArg- NH ₂ DArg(NO ₂)
F5bz F5c		PzO DArg- (NO ₂)	Arg- (NO ₂)						pAmb	Cmp CpG	Arg- OMe DArg DArg- NH ₂ DArg(NO ₂)
F5pa Gun										DhPhe Dpr(F bz)	Arg- OMe DArg DArg- NH ₂ DArg(NO ₂)
Hxa										Dpr(Pa a)	Arg- OMe DArg DArg- NH ₂ DArg(NO ₂)
Mca Mcg										F5F F5F- NH ₂	Arg- OMe DArg DArg- NH ₂ DArg(NO ₂)

Moti
Pcc
Ppa
Pya


Saa
Ste

Tfmc


Hphe
Ica
Igl
Igl-
NH₂
Ileu
Lys(C
H₃)₃
Lys(F
5bz)
Mapa
MBC
MFF
Nc6G
Nc7G
NMF
OBS
OBT
OBY
OC2Y
Oic
Oic-
NH₂
PABz
Pac
PaF(F
5c)
PaF(F
bz)
PaF(M
cg)
PaF(P
pa)
PaF(Si
n)
pAmb
pAPa
PCF
PdF
PFF
PFF-
NH₂
Phe
PNF
Thi
Tic
Trp
Trx
Tyr

100355662.122801

2. A compound of the formula:



wherein X is a linker group having 2-5 functional groups or is absent, $n = 1$, and Formula III is



wherein R, A, B, C, D, E, and F are selected from the following or may be absent, and wherein F is not Arg or an Arg derivative:

R	A 1	B 2	C 3	D 4	E 5	F 6
Absent or	Absent or	Absent or	Absent or	Absent or	Absent or	Absent or
2,2Dp 3,3Dp	DArg DArg(NO ₂)	Arg	Add Aud	2Nal 3Pal	1Nal 2Nal	2Nal 3Pal
Aaa Ac Aca Boc Chc Cin			Ava Eac Lys Pac	Arg Arg(Tos) Atcp D2Nal DArg DArg(Tos)	2Nap 3Pal Apa Arg Arg-NH ₂ Asp	ABza ABza Ama Ampy Ampz Apa
Ctim Dca Dcg Dhq Dmac Dns				DF5F DIgl DPFF Eac F5F Gly	Atc Atcp Bip BtA Cys(Meb) Cys(SO ₃ H)	Api Aptp Aqd Aqu Arg(H) Arg-CH ₂ OH
Dpa F5c F5pa F5po Gbc Gun Hxa Mcg Mse Pya Seb Sin				His Igl mABz OC2Y Pac PFF	D2Nal DArg DArg-NH ₂ F5F Glu Gly Igl Inp Iqa mABz MC2Y N-Dmb- Tyr(Bz)- OMe OC2Y	Arg-NH ₂ Arg-OMe Asp Asp(Aqu) Atcp Atmp AtmpO Atpm Cyh Dmab Dmm Dmp
Sul						Dpea

Tfmc
Tha

OCIY
Oic


pABz
PaF(Mes)
PFF
Tic
tLeu

Trp


Try
Try(Bzl)
Tyr
Arg(NO₂)

Dpma
Dpr(Dcg-2-Nap)
Ecap
F5F-NH₂
GaP
mA₂Bz
mA₂Bz(Dc
g)
mA₂Bz(Gu
n)
mABz
Mapp
Matp
MatpO
pABz
PaF
PaF(Dcg)
PaF(Mcg)
PaF-NH₂
PFF-NH₂
PgF
PzO
Sud
Thm
Thm
Tpac
Tpac
Tyr(Bz)O
Me

3. A compound of the formula:




wherein X is a linker group having 2-5 functional groups or is absent, n = 1, and Formula IV is




wherein A, B, C, D, E, F, G, H, I, J, K and L are selected from the following or may be absent:

A	B	C	D	E	F	G	H	I	J	K	L
0	1	2	3	4	5	6	7	8	9	10	11
Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent
or	or	or	or	or	or	or	or	or	or	or	or
DArg	Arg	Pro	Lys	Pro	DTrp	Gln	DTrp	Phe	DTrp	Leu(r)	Leu-NH ₂
	DArg					DNM					Leu
						F					

4. A compound of the formula:




wherein X is a linker group having 2-5 functional groups or is absent; n = 1; c indicates cyclization, the site of cyclization selected from the group consisting of the c-terminus, and a side chain functional group; and Formula V is



wherein X, A, B, C, D, E, F, G, H, I, J, and K are selected from the following or may be absent:

X	A	B	C	D	E	F	G	H	I	J	K
	-1	0	1	2	3	4	5	6	7	8	9
Absent or α-Aca 3,3Dp	Absent or Ava BALa DmK Glt Lys Suc	Absent or DArg DNik DPaF DPzK DPzO	Absent or Arg NiK PzO	Absent or Pro	Absent or Hyp	Absent or Gly	Absent or Add Aud Ava BALa DNMF Eac Igl Thi	Absent or DArg Ser Thr Nig Pac Phe	Absent or DDab DDpr DF5F DIgl DLys DOm DPaF	Absent or DTrp F5F Lys Nc7G Oic PaF PFF Phe	Absent or Arg Leu NiK PaF 3Pal

5. A compound of the formula



wherein [ACA] is a compound of claim 1, 2, 3, or 4.

6. A method to inhibit tumor growth in an animal in need of such inhibition, comprising administering a compound selected from the group consisting of a compound of claim 1, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg, DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nig-Arg, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg, Lys-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DTic-ChG, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Nc7G-Arg, and DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Oic-Arg.

7. A method to inhibit tumor growth in an animal in need of such inhibition, comprising administering a compound selected from the group consisting of a compound of claim 2, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg, DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nig-Arg, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg, Lys-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DTic-ChG, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Nc7G-Arg, and DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Oic-Arg.
8. A method to inhibit tumor growth in an animal in need of such inhibition, comprising administering a compound selected from the group consisting of a compound of claim 3, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg, DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nig-Arg, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg, Lys-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DTic-ChG, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Nc7G-Arg, and DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Oic-Arg.
9. A method to inhibit tumor growth in an animal in need of such inhibition, comprising administering a compound selected from the group consisting of a compound of claim 4, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg, DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nig-Arg, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg, Lys-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DTic-ChG, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Nc7G-Arg, and DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Oic-Arg.
10. A method to inhibit tumor growth in an animal in need of such inhibition, comprising administering a compound selected from the group consisting of a compound of claim 5, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg, DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nig-Arg, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg, Lys-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DTic-ChG, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Nc7G-Arg, and DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Oic-Arg.
11. A method to induce apoptosis, comprising administering a compound selected from the group consisting of a compound of claim 1, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg, DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nig-Arg, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg,

Lys-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DTic-ChG,
DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Nc7G-Arg, and
DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Oic-Arg.

12. A method to induce apoptosis, comprising administering a compound selected from the group consisting of a compound of claim 2,

DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg,
DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nig-Arg,
DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg,
Lys-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DTic-ChG,
DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Nc7G-Arg, and
DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Oic-Arg.

13. A method to induce apoptosis, comprising administering a compound selected from the group consisting of a compound of claim 3,

DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg,
DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nig-Arg,
DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg,
Lys-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DTic-ChG,
DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Nc7G-Arg, and
DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Oic-Arg.

14. A method to induce apoptosis, comprising administering a compound selected from the group consisting of a compound of claim 4,

DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg,
DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nig-Arg,
DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg,
Lys-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DTic-ChG,
DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Nc7G-Arg, and
DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Oic-Arg.

15. A method to induce apoptosis, comprising administering a compound selected from the group consisting of a compound of claim 5,

DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg,
DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nig-Arg,
DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg,
Lys-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DTic-ChG,
DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Nc7G-Arg, and
DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Oic-Arg.